Stock AZN ASTRAZENECA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:22 2024-05-24 am EDT 		5-day change 1st Jan Change
12,296 GBX -0.87% Intraday chart for AstraZeneca PLC +1.54% +16.00%
May. 24 Innate Pharma: five abstracts selected for ASCO CF
May. 24 Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 132,331 131,461 181,878 210,243 209,128 242,963 - -
Enterprise Value (EV) 1 144,340 143,328 206,261 233,166 231,638 263,612 257,061 250,125
P/E ratio 97.9 x 41 x 1,468 x 64.3 x 35.4 x 27.5 x 23.5 x 21.2 x
Yield 2.78% 2.8% 2.44% 2.14% 2.15% 1.96% 2.07% 2.16%
Capitalization / Revenue 5.43 x 4.94 x 4.86 x 4.74 x 4.57 x 4.71 x 4.38 x 4.14 x
EV / Revenue 5.92 x 5.38 x 5.51 x 5.26 x 5.06 x 5.11 x 4.63 x 4.27 x
EV / EBITDA 21.6 x 17.2 x 27.2 x 25.2 x 17.1 x 14.9 x 12.7 x 11.4 x
EV / FCF 72.5 x 37.3 x 42.3 x 26.7 x 25.8 x 30.4 x 21.9 x 18.3 x
FCF Yield 1.38% 2.68% 2.36% 3.74% 3.88% 3.29% 4.57% 5.45%
Price to Book 10 x 8.41 x 4.24 x 5.67 x 5.38 x 5.87 x 5.26 x 4.64 x
Nbr of stocks (in thousands) 1,311,913 1,312,660 1,549,159 1,549,528 1,549,926 1,550,235 - -
Reference price 2 100.9 100.1 117.4 135.7 134.9 156.7 156.7 156.7
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 24,384 26,617 37,417 44,351 45,811 51,622 55,478 58,645
EBITDA 1 6,686 8,311 7,586 9,237 13,580 17,667 20,209 22,035
EBIT 1 6,436 7,340 9,928 13,350 14,534 16,860 19,079 20,708
Operating Margin 26.39% 27.58% 26.53% 30.1% 31.73% 32.66% 34.39% 35.31%
Earnings before Tax (EBT) 1 1,548 3,916 -265 2,501 6,899 10,901 13,037 14,422
Net income 1 1,335 3,196 112 3,288 5,961 8,881 10,386 11,641
Net margin 5.47% 12.01% 0.3% 7.41% 13.01% 17.2% 18.72% 19.85%
EPS 2 1.030 2.440 0.0800 2.110 3.810 5.693 6.664 7.394
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,684 11,745 13,640
FCF margin 8.16% 14.42% 13.02% 19.65% 19.61% 16.82% 21.17% 23.26%
FCF Conversion (EBITDA) 29.76% 46.18% 64.22% 94.37% 66.16% 49.16% 58.12% 61.9%
FCF Conversion (Net income) 149.06% 120.09% 4,350% 265.12% 150.71% 97.79% 113.09% 117.17%
Dividend per Share 2 2.800 2.800 2.870 2.900 2.900 3.076 3.245 3.382
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - 12,011 - 11,390 10,771 - 10,982 11,207 - 10,879 11,416 11,492 12,024 12,679 12,673 12,887 13,491 13,530 13,805
EBITDA 1 - - - 1,900 - 2,187 1,896 - 2,579 2,574 - - 3,732 - - - 4,396 4,404 5,260 - -
EBIT 1 - - - 3,318 - 3,961 3,365 - 3,413 2,610 - 3,946 4,291 3,545 2,752 4,310 4,170 4,244 4,008 - -
Operating Margin - - - 27.62% - 34.78% 31.24% - 31.08% 23.29% - 36.27% 37.59% 30.85% 22.89% 33.99% 32.91% 32.94% 29.71% - -
Earnings before Tax (EBT) 1 - - - -636 - 553 247 - 922 778 - 2,262 2,088 1,652 897 2,800 2,361 2,740 3,099 - -
Net income 1 - - - -347 - 386 360 - 1,640 901 - 1,803 1,818 1,378 959 2,179 2,362 2,279 2,501 - -
Net margin - - - -2.89% - 3.39% 3.34% - 14.93% 8.04% - 16.57% 15.93% 11.99% 7.98% 17.19% 18.64% 17.68% 18.54% - -
EPS 2 - - - -0.2200 - 0.2500 0.2300 - 1.050 0.5800 - 1.160 1.170 0.8900 0.6200 1.410 1.514 1.460 1.605 - -
Dividend per Share 2 0.9000 1.900 0.9000 1.970 1.970 - 0.9300 0.9300 - 1.970 1.970 - 0.9300 - 1.970 - 0.8875 0.7750 1.438 0.8750 0.8750
Announcement Date 7/30/20 2/11/21 7/29/21 2/10/22 2/10/22 4/29/22 7/29/22 7/29/22 11/10/22 2/9/23 2/9/23 4/27/23 7/28/23 11/9/23 2/8/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,009 11,867 24,383 22,923 22,510 20,649 14,097 7,162
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.796 x 1.428 x 3.214 x 2.482 x 1.658 x 1.169 x 0.6976 x 0.325 x
Free Cash Flow 1 1,990 3,838 4,872 8,717 8,984 8,684 11,745 13,640
ROE (net income / shareholders' equity) 35.6% 36.7% 27.5% 27.2% 29.8% 30.4% 31.6% 30.8%
ROA (Net income/ Total Assets) 2.19% 4.99% 8.77% 3.26% 11.5% 9.36% 10.6% 11.4%
Assets 1 61,015 64,053 1,277 100,924 51,935 94,910 98,075 101,909
Book Value Per Share 2 10.10 11.90 27.70 23.90 25.10 26.70 29.80 33.80
Cash Flow per Share 2 2.280 3.660 4.180 6.290 6.620 8.540 10.40 11.60
Capex 1 979 961 1,091 1,091 1,361 1,990 1,957 1,935
Capex / Sales 4.01% 3.61% 2.92% 2.46% 2.97% 3.86% 3.53% 3.3%
Announcement Date 2/14/20 2/11/21 2/10/22 2/9/23 2/8/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AstraZeneca PLC

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7 USD
Average target price
170.1 USD
Spread / Average Target
+8.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
PFIZER, INC. Stock Pfizer, Inc.
+0.31% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Financials AstraZeneca PLC